Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults
Open Access
- 1 April 2010
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (4) , 537-544
- https://doi.org/10.1128/cvi.00436-09
Abstract
This study evaluated the safety, tolerability, and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, when administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine, in subjects aged 11 to 25 years. Subjects received either MenACWY-CRM and Tdap, MenACWY-CRM and saline placebo, or Tdap and saline placebo. No significant increase in reactogenicity and no clinically significant vaccine-related adverse events (AEs) occurred when MenACWY-CRM and Tdap were administered concomitantly. Similar immunogenic responses to diphtheria, tetanus, and meningococcal (serogroups A, C, W-135, and Y) antigens were observed, regardless of concomitant vaccine administration. Antipertussis antibody responses were comparable between vaccine groups for filamentous hemagglutinin and were slightly lower, although not clinically significantly, for pertussis toxoid and pertactin when the two vaccines were administered concomitantly. These results indicate that the investigational MenACWY-CRM vaccine is well tolerated and immunogenic and that it can be coadministered with Tdap to adolescents and young adults.Keywords
This publication has 17 references indexed in Scilit:
- A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy AdolescentsThe Pediatric Infectious Disease Journal, 2009
- New adolescent vaccination recommendations and how to make them “stick”Current Opinion in Pediatrics, 2007
- Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric PatientsPediatrics, 2005
- Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United StatesPublished by American Academy of Pediatrics (AAP) ,2005
- Effect of Vaccination with Carrier Protein on Response to Meningococcal C Conjugate Vaccines and Value of Different Immunoassays as Predictors of ProtectionInfection and Immunity, 2002
- Outbreak of W135 Meningococcal Disease in 2000: Not Emergence of a New W135 Strain but Clonal Expansion within the Electophoretic Type–37 ComplexThe Journal of Infectious Diseases, 2002
- The Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996The Journal of Infectious Diseases, 1999
- A Comparative Efficacy Trial in Germany in Infants Who Received Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP Vaccine, or DT VaccinePediatrics, 1998
- Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infantsThe Journal of Pediatrics, 1996
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969